Submission supported by positive results from global, Phase 3 4WHIM clinical trial;U.S. regulatory approval in WHIM syndrome granted in ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

Now, Bernhagen and colleagues, writing in Nature Medicine, have identified MIF as a ligand for the CXC-chemokine receptors CXCR2 and CXCR4, and suggest that targeting MIF could be used as an ...

Other targets for entry inhibitors include two co-receptors on the cell surface—CCR5 and CXCR4—which together with CD4 mediate virus binding and membrane fusion 3. As CCR5, but not CXCR4 ...

Mavorixafor is a selective CXCR4 receptor antagonist approved in the U.S. and marketed by X4 as XOLREMDI®, an oral, once-daily treatment for patients 12 years of age and older with WHIM syndrome, a ...

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered ...

Mavorixafor is a selective CXCR4 receptor antagonist approved in the U.S. and marketed by X4 as XOLREMDI®, an oral, once-daily treatment for patients 12 years of age and older with WHIM syndrome ...

Before fusion of the HIV viral envelope and host cell membrane can occur, an HIV glycoprotein complex consisting of glycoproteins gp41 and gp120 must bind with the CD4 receptor on the membrane of ...

Chemokines are a subclass of cytokines, a large family of small secreted proteins that communicate via G protein-coupled ...